Dexamethasone-induced muscle atrophy and bone loss in six genetically diverse collaborative cross founder strains

Bao Ngoc Nguyen1,2, Soyeon Hong3, Sowoon Choi2

  • 1College of Dentistry, Gangneung Wonju National University, Gangneung, Gangwon-do, Republic of Korea.

PubMed
Abstract

Insights

Ginsenoside Rg3 improved bone and muscle health in mice with osteosarcopenia, showing strain-specific benefits and correlations with immune function. This highlights Rg3

Area of Science:

  • Pharmacology
  • Genetics
  • Gerontology

Background:

  • Osteosarcopenia, characterized by bone and muscle mass loss, increases fracture and disability risks in older adults.
  • Understanding the impact of phytochemicals like Rg3 on osteosarcopenia is crucial for developing targeted interventions.
  • Genetic diversity influences responses to disease and treatment, necessitating studies using varied genetic models.

Purpose of the Study:

  • To investigate the effects of Rg3, a ginsenoside, on musculoskeletal traits and immune function in different mouse strains.
  • To explore the correlation between Rg3 treatment, genetic background, and osteosarcopenia-related parameters.
  • To establish a public web resource (Rg3-OsteoSarco) for phenotyping data.

Main Methods:

  • Six Collaborative Cross (CC) founder mouse strains were induced with muscle atrophy and bone loss using dexamethasone.
  • Mice received either Rg3 treatment (20 mg/kg) or a control, with half of each strain treated.
  • Musculoskeletal traits, gene expression, and immune function were assessed, with data analyzed using two-way ANOVA.

Main Results:

  • Rg3 significantly enhanced grip strength, running performance, and expression of muscle/bone health genes across strains.
  • Specific improvements in strength, performance, bone area, muscle mass, and gene expression were noted in PWK/PhJ mice.
  • Significant correlations between muscle, bone, and immune functions were observed post-Rg3 administration.

Conclusions:

  • Genetic background critically influences the response to Rg3 in osteosarcopenia models.
  • Rg3 demonstrates potential as a therapeutic agent for age-related bone and muscle loss.
  • Collaborative Cross founder strains are valuable for personalized nutrition research, moving beyond single inbred models.